Tirabrutinib

Name: Tirabrutinib in Primary central nervous system lymphoma: Dosage forms and strengths
Published: 2026-09-14T15:39:06-04:00

Primary central nervous system lymphoma

Manufacturer: Deciphera Pharmaceuticals
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the fiscal year ending March 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Dosage forms and strengths

2 evidence topics · 2 sources

Dosage form: Japan

“Velexbru Tablets 80 mg” (opens the source at this quote in a new tab)

Research-use chemical safety data sheet

“Trade name: ONO-4059” (opens the source at this quote in a new tab)
“CAS Number: 1351636-18-4” (opens the source at this quote in a new tab)
“This product is for research use - Not for human or veterinary diagnostic or therapeutic use.” (opens the source at this quote in a new tab)